Seroatlas · Human Serome Atlas

SLAMF7

SLAM family member 7

Also known as: 19A, CD319, CRACC, CS1, SLAF7_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NQ25
Gene: SLAMF7
Ensembl: ENSG00000026751
Chromosome: 1
Canonical length: 335 aa
Protein class: CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Enables identical protein binding activity. Predicted to be involved in T cell activation and immune response. Predicted to act upstream of or within regulation of natural killer cell activation. Located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

335 residues, UniProt reviewed canonical sequence.

>Q9NQ25|SLAMF7
     1  MAGSPTCLTL IYILWQLTGS AASGPVKELV GSVGGAVTFP LKSKVKQVDS IVWTFNTTPL
    61  VTIQPEGGTI IVTQNRNRER VDFPDGGYSL KLSKLKKNDS GIYYVGIYSS SLQQPSTQEY
   121  VLHVYEHLSK PKVTMGLQSN KNGTCVTNLT CCMEHGEEDV IYTWKALGQA ANESHNGSIL
   181  PISWRWGESD MTFICVARNP VSRNFSSPIL ARKLCEGAAD DPDSSMVLLC LLLVPLLLSL
   241  FVLGLFLWFL KRERQEEYIE EKKRVDICRE TPNICPHSGE NTEYDTIPHT NRTILKEDPA
   301  NTVYSTVEIP KKMENPHSLL TMPDTPRLFA YENVI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLAMF7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 58 nTPM

Expression across tissuesHPA

Tissue

tonsil: 58 nTPM
lymph node: 48 nTPM
spleen: 40 nTPM
appendix: 33 nTPM
stomach: 32 nTPM
colon: 31 nTPM

Single-cell type

plasma cells: 395 nCPM
pdcs: 159 nCPM
nk-cells: 101 nCPM
cdc: 96 nCPM
t-cells: 51 nCPM
macrophages: 39 nCPM

Immune cell

gdT-cell: 101 nTPM
plasmacytoid DC: 90 nTPM
MAIT T-cell: 77 nTPM
memory CD8 T-cell: 69 nTPM
NK-cell: 56 nTPM
non-classical monocyte: 54 nTPM

Brain region

cerebral cortex: 1.1 nTPM
choroid plexus: 1.1 nTPM
pons: 1 nTPM
white matter: 0.9 nTPM
spinal cord: 0.7 nTPM
medulla oblongata: 0.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.71
gnomAD pLI: 0.04
gnomAD missense Z: 0.94
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

identical protein binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLAMF7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

SH2D1B

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLAMF7 as an antibody target. Whether an autoantibody or antibody against SLAMF7 could matter depends on whether native SLAMF7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLAMF7 is annotated at the cell surface, where native SLAMF7 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLAMF7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...